ArticleGlobal medical genetics2026
Can automated copy number variation pathogenicity prediction tools replace manual review under the ACMG framework? A clinical validation.
Article in Global medical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Copy Number Variation (CNV) is associated with numerous complex diseases, yet their pathogenicity assessment remains heavily dependent on manual expert review, a process that is cumbersome and time-consuming. Although a variety of automated tools for CNV pathogenicity prediction have been developed, systematic assessments of their performance and clinical generalizability under the five-category classification framework defined by ACMG standards remain scarce. Methods: This study constructed an expert-reviewed CNV benchmark dataset. Under the ACMG five-category system, it systematically compared the classification prediction capabilities of five prediction tools across both deletion and duplication CNV samples. Furthermore, it assessed their applicability in real clinical samples and evaluated potential biases towards specific variations. Results: The study indicates that different tools exhibit performance variations and specialised strengths across different classification tasks, yet overall capability in distinguishing clinical risk boundaries across the five categories remains inadequate. Among these, AnnotSV demonstrated outstanding performance in predicting pathogenic samples, achieving accuracy rates of 95.16% and 86.39% on the deletion and duplication benchmark datasets respectively. ClassifyCNV demonstrated optimal performance in variant of uncertain significance classification with an accuracy of 95.33%. Furthermore, all models exhibited significantly superior five-category discrimination capabilities for deletion samples compared with duplication samples, revealing pronounced performance biases across variant types. Conclusion: Current automated CNV prediction tools demonstrate higher discriminatory capacity for deletion variants than for duplications; however, they remain insufficient to fully replace manual expert review within the ACMG five-category framework. Further optimisation using multicentre, consistently curated clinical gold-standard datasets is required to improve their reliability and clinical applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.